Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses some promising agents in development for the treatment of polycythemia vera (PV), including KRT-232, givinostat, and LSD inhibitors. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.